Market open
Artelo Biosciences Inc./$ARTL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Artelo Biosciences Inc.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Ticker
$ARTL
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
6
ISIN
US04301G5080
Website
ARTL Metrics
BasicAdvanced
$3.3M
-
-$3.05
1.06
-
Price and volume
Market cap
$3.3M
Beta
1.06
52-week high
$1.40
52-week low
$0.82
Average daily volume
820K
Financial strength
Current ratio
1.443
Quick ratio
1.319
Long term debt to equity
2.415
Total debt to equity
3.64
Management effectiveness
Return on assets (TTM)
-71.22%
Return on equity (TTM)
-134.52%
Valuation
Price to book
1.15
Price to tangible book (TTM)
4.01
Price to free cash flow (TTM)
-0.386
Growth
Earnings per share change (TTM)
-2.85%
3-year earnings per share growth (CAGR)
-17.50%
ARTL News
AllArticlesVideos
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis
GlobeNewsWire·2 weeks ago
Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025
GlobeNewsWire·1 month ago
Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Artelo Biosciences Inc. stock?
Artelo Biosciences Inc. (ARTL) has a market cap of $3.3M as of May 09, 2025.
What is the P/E ratio for Artelo Biosciences Inc. stock?
The price to earnings (P/E) ratio for Artelo Biosciences Inc. (ARTL) stock is 0 as of May 09, 2025.
Does Artelo Biosciences Inc. stock pay dividends?
No, Artelo Biosciences Inc. (ARTL) stock does not pay dividends to its shareholders as of May 09, 2025.
When is the next Artelo Biosciences Inc. dividend payment date?
Artelo Biosciences Inc. (ARTL) stock does not pay dividends to its shareholders.
What is the beta indicator for Artelo Biosciences Inc.?
Artelo Biosciences Inc. (ARTL) has a beta rating of 1.06. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.